Royalty Pharma to Announce Second Quarter 2025 Financial Results on August 6, 2025
Royalty Pharma (NASDAQ:RPRX) has scheduled its second quarter 2025 financial results announcement for Wednesday, August 6, 2025, before U.S. markets open. The company will host a conference call and webcast at 8:00 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on Royalty Pharma's website for a minimum of 30 days following the event.
Royalty Pharma (NASDAQ:RPRX) ha programmato l'annuncio dei risultati finanziari del secondo trimestre 2025 per mercoledì 6 agosto 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una diretta webcast alle 8:00 a.m. ora della costa orientale nello stesso giorno.
Gli investitori possono accedere ai dettagli della conference call e alla diretta webcast tramite la pagina Investitori del sito web aziendale. La registrazione della chiamata e della webcast resterà disponibile sul sito di Royalty Pharma per almeno 30 giorni dopo l'evento.
Royalty Pharma (NASDAQ:RPRX) ha programado el anuncio de sus resultados financieros del segundo trimestre de 2025 para el miércoles 6 de agosto de 2025, antes de la apertura de los mercados en EE.UU. La compañía realizará una conferencia telefónica y una transmisión en vivo a las 8:00 a.m., hora del este ese mismo día.
Los inversores pueden acceder a los detalles de la conferencia y la transmisión en vivo a través de la página de Inversores en el sitio web de la compañía. La repetición de la llamada y la transmisión estará disponible en el sitio web de Royalty Pharma durante al menos 30 días después del evento.
Royalty Pharma (NASDAQ:RPRX)는 2025년 2분기 재무 실적 발표를 2025년 8월 6일 수요일 미국 시장 개장 전으로 예정했습니다. 회사는 같은 날 동부 표준시 오전 8시에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다.
투자자들은 회사 웹사이트의 투자자 페이지를 통해 컨퍼런스 콜 상세 정보와 라이브 웹캐스트에 접속할 수 있습니다. 컨퍼런스 콜과 웹캐스트 녹화는 행사 후 최소 30일간 Royalty Pharma 웹사이트에서 다시보기로 제공됩니다.
Royalty Pharma (NASDAQ:RPRX) a programmé l'annonce de ses résultats financiers du deuxième trimestre 2025 pour le mercredi 6 août 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et une diffusion en direct à 8h00, heure de l'Est le même jour.
Les investisseurs peuvent accéder aux détails de la conférence téléphonique et à la diffusion en direct via la page Investisseurs du site web de la société. La rediffusion de la conférence et de la diffusion restera disponible sur le site de Royalty Pharma pendant au moins 30 jours après l'événement.
Royalty Pharma (NASDAQ:RPRX) hat die Bekanntgabe der Finanzergebnisse für das zweite Quartal 2025 für Mittwoch, den 6. August 2025, vor Öffnung der US-Märkte, geplant. Das Unternehmen wird am selben Tag um 8:00 Uhr Eastern Time eine Telefonkonferenz und einen Webcast veranstalten.
Investoren können die Details zur Telefonkonferenz und den Live-Webcast über die Investorenseite der Unternehmenswebsite abrufen. Eine Aufzeichnung der Telefonkonferenz und des Webcasts wird mindestens 30 Tage nach der Veranstaltung auf der Website von Royalty Pharma verfügbar sein.
- None.
- None.
NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) report Q2 2025 earnings?
What time is Royalty Pharma's Q2 2025 earnings call?
How can I access Royalty Pharma's Q2 2025 earnings call?
How long will Royalty Pharma's Q2 2025 earnings call replay be available?
